ADOC regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
Overview
ADOC regimen refers to an immunochemotherapy regimen consisting of doxorubicin (Adriamycin), cisplatin (cis-Diamminedichloroplatinum), vincristine (Oncovin), cyclophosphamide used to treat invasive thymoma.[1]
Regimen
Regimen
AAdriamycin
DCisplatin (Cis-Diamminedichloroplatinum)
OVincristine (Oncovin)
CCyclophosphamide
References
References
- ↑ 1.0 1.1 Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F; et al. (1991). “Chemotherapy for invasive thymoma. A 13-year experience”. Cancer. 68 (1): 30–3. PMID 2049749.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH